Performance of the TruGene human immunodeficiency virus type 1 genotyping kit and OpenGene DNA sequencing system on clinical samples diluted to approximately 100 copies per milliliter

Clinical and Vaccine Immunology

Volumn 13, Issue 2, 2006, Pages 235-238

  Gale, Howard B ^a   Kan, Virginia L ^a   Shinol, Rebecca C ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; RNA EXTRACTION;

ANTI-HIV AGENTS; BASE SEQUENCE; CODON; DNA, VIRAL; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 33644926674     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.2.235-238.2006     Document Type: Article

References (8)

1. Aleman, S., K. Soderbarg, U. Visco-Comandini, G. Sitbon, and A. Sonnerborg. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044.
2. Department of Health and Human Services Panel on Clinical Practices. 6 October 2005, posting date. Treatment of HIV infection: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. [Online.] http://www.aidsinfo.nih.gov/guidelines/.
3. Elbeik T., B. S. Hoo, M. E. Campodonico, J. Dileanis, F. F. Fay, R. L. Bortolozzi, M. S. Benetti, O. H. Fay, N. Marlowe, O. Petrauskene, D. Chernoff, L. Smith, and V. L. Ng. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/ml that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy. J. Hum. Virol. 4:317-328.
4. Hermankova, M., S. C. Ray, C. Ruff, M. Powell-Davis, R. Ingersoll, R. T. D'Aquila, T. C. Quinn, J. D. Siliciano, R. F. Siliciano, and D. Persaud. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA 286:196-207.
5. Kuritzkes, D. R., R. M. Grant, P. Feorino, M. Griswol, M. Hoover, R. Young, S. Day, R. M. Lloyd, C. Reid, G. F. Morgan, and D. L. Winslow. 2003. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system. J. Clin. Microbiol. 41:1594-1599.
6. Mackie, N., S. Dustan, M. O. McClure, J. N. Weber, and J. R. Clarke. 2004. Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J. Virol. Methods 119:73-78.
7. Nettles, R. E., T. L. Kieffer, R. P. Simmons, J. Cofrancesco, Jr., R. D. Moore, J. E. Gallant, D. Persaud, and R. F. Siliciano. Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin. Infect. Dis. 39:1030-1037.
8. Parkin, N. T., S. D. Deeks, M. T. Wrin, J. Yap, R. M. Grant, K. H. Lee, D. Heeren, N. S. Hellmann, and C. J. Petropoulos. 2000. Loss of antiretroviral drug susceptibility at low viral load during early virologic failure in treatment-experienced patients. AIDS 14:2877-2887.